Concurrent elevations of VEGF, osteopontin and MCP-1 serum levels are independent predictors of survival in patients with diffuse large B-cell lymphoma

Acta Haematologica

Volumn 136, Issue 1, 2016, Pages 52-61

  Duletić Načinović, Antica ^a   Gačić, Vedrana ^c   Valković, Toni ^a   Lučin, Ksenija ^b   Fišić, Elizabeta ^a   Žuvić Butorac, Marta ^b   Seili Bekafigo, Irena ^a   Jonjić, Nives ^b  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c University Clinical Hospital   (Bosnia and Herzegovina)

Author keywords

CCL2; Chemokines; Diffuse large B cell lymphoma; MCP 1; Osteopontin; VEGF

Indexed keywords

BIOLOGICAL MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; TUMOR REGRESSION; BLOOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS;

HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; OSTEOPONTIN; PILOT PROJECTS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84973915352     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000444624     Document Type: Article

References (50)

1. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 2006 7 379-391
2. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033
3. Hagberg H, Gisselbrecht C; CORAL Study Group: Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study Ann Oncol 2006 17(suppl 4) iv31-iv32
4. Sehn LH. Early detection of patients with poor risk diffuse large B-cell lymphoma. Leuk Lymphoma 2009; 50: 1744-1747
5. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, Sancho JM, Arenillas L, Serrano S, Escoda L, Martínez S, Valera A, Martínez A, Jares P, Pinyol M, García-Herrera A, Martínez-Trillos A, Giné E, Villamor N, Campo E, Colomo L, López-Guillermo A; Grup per l Estudi dels Limfomes de Catalunya I Balears (GELCAB): Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy Blood 2011 117 4836-4843
6. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861
7. Lejeune M, Alvaro T. Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma. Haematologica 2009; 94: 16-21
8. Junttila MR, De Sauvag FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501: 346-354
9. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project: Stromal gene signatures in large-B-cell lymphomas N Engl J Med 2008 59 2313-2323
10. Mangi MH, Newland MC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2000; 111: 43-51
11. Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS, An CS. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 2008; 134: 381-387
12. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G. Angiogenic growth factor and endostatin in non-Hodgkin s lymphoma. Br J Haematol 1999; 106: 504-509
13. Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, Higashihara M, Hirano M. Simultaneous elevation of the serum concentration of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin s lymphoma. Eur J Hematol 2002; 68: 91-100
14. Pedersen LM, Jurgensen GW, Johnsen HE. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br J Haematol 2005; 128: 813-819
15. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin s lymphoma. Blood 1997; 90: 3167-3172
16. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712-3718
17. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004; 121: 228-241
18. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for VEGF and osteopontin. Clin Cancer Res 2007: 13: 816-823
19. Caers J, Gunthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol 2006; 132: 469-477
20. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010; 103: 861-869
21. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40
22. Bernardini G, Rimbatti D, Spinetti G, Morbidelli L, Ziche M, Santoni A, Capogrossi MC, Napolitano M. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003; 273: 83-101
23. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405-1407
24. Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP. The monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) in Hodgkin s disease and in solid tumors. Mol Pathol 1998; 51: 273-276
25. Valkovic T, Duletić-Načinović A, Stifter S, Hasan M, Hadžisejdic I, Zombori D, Grahovac B, Jonjić N. Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma. Clin Exp Med 2010; 10: 229-235
26. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008
27. Carbone PP, Kaplan HS, Mushoff K, Smithers DW, Tubiana M. Report of the Committee in Hodgkin s Disease Staging Classification. Cancer Res 1971; 31: 1860-1861
28. Hermans J, Krol AD, van Groningen K, Kluin-Nelemans JC, Kramer MH, Noordjik EM. International prognostic index for aggressive non-Hodgkin s lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460-1463
29. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655
30. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
31. Guo Q, Wang JJ, Li F, Yang HL, Yu Y, Zhao ZG, Wang XF, Wang YF, Zhang YZ. Expressions of VEGF and CXCR4 in diffuse large B cell lymphoma and their clinical significance (in Chinese). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013; 21: 383-386
32. Okur FV, Karadeniz C, Buyukpamukcu M, Oguz A, Yucel A, Cinaz P, Emir S, Varan A. Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma. Pediatr Blood Cancer 2010; 55: 1272-1277
33. Chagan-Yasutan H, Tsukasaki K, Takahashi Y, Oguma S, Harigae H, Ishii N, Zhang J, Fukumoto M, Hattori T. Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia. Leuk Res 2011; 35: 1484-1490
34. Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA, Mazzarino MC. Elevated serum levels of osteopontin in HCV-Associated lymphoproliferative disorders. Cancer Biol Ther 2005; 4: 1192-1194
35. Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. Eur J Haematol 2012; 89: 395-402
36. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893-2902
37. Dvorak HF. Vascular permeability to plasma, plasma proteins, and cells: an update. Curr Opin Hematol 2010; 17: 225-229
38. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of antiangiogenic drugs. Cancer Cell 2012; 21: 82-91
39. Laxmanan S, Robertson SW, Wang E, Lau JS, Briscoe DM, Mukhopadhyay D. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun 2005; 334: 193-198
40. Weber GF. The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Protemics 2011; 8: 263-288
41. Valković T, Babarović E, Lučin K, Štifter S, Aralica M, Pećanić S, Seili-Bekafigo I, Duletić-Načinović A, Nemet D, Jonjić N. Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma. Biomed Res Int 2014; 2014: 513170
42. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O Neill BP, Lai WR, Park PJ, McKinney M. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111: 3200-3210
43. Yuan J, Gu K, He J, Sharma S. Preferential upregulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression. Hum Pathol 2013; 44: 606-611
44. Starr JS, Jiang L, Li Z, Qiu Y, Menke DM, Tun HW. CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement. Clin Lymphoma Myeloma Leuk 2013; 13: 597-601
45. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68: 152-161
46. Sfiridaki A, Miyakis S, Pappa C, Tsirakis G, Alegakis A, Kotsis V, Stathopoulos E, Alexandrakis M. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J Hematol Oncol 2011; 4: 22-25
47. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326
48. Mazur G, Jaskula E, Kryczek I, Dlubek D, Butrym A, Wróbel T, Lange A, Kuliczkowski K. Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin s lymphoma. Folia Histochem Cytobiol 2011; 49: 240-247
49. Paydas S, Seydaoglu G, Ergin M, Erdogan S, Yavuz S. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50: 366-373
50. Cacciatore M, Guarnotta C, Calvaruso M, Sangaletti S, Florena AM, Franco V, Colombo MP, Tripodo C. Microenvironment-centered dynamics in aggressive B-cell lymphomas. Adv Hematol 2012; 2012: 138079